HDII.US Hypertension Diagnostics Inc
- Market cap
- USD 28.5K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is HDII.US undervalued?
Graham numberThe Graham number of Hypertension Diagnostics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hypertension Diagnostics Inc fundamental analysis
No fundamental analysis for Hypertension Diagnostics Inc yet.
Hypertension Diagnostics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hypertension Diagnostics Inc
Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provid…
Full company profileHypertension Diagnostics Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hypertension Diagnostics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2009 | 2010 | 2011 | 2012 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 503K | 1.39M | 1.39M | 3.16M | 3.57M | 3.68M | 3.79M | - | - | - | - |
| Gross Profit | 492K | 1.11M | 1.11M | -112K | 551K | 752K | 954K | - | - | - | - |
| Operating Income | -262K | -366K | 396K | -1.36M | -656K | -403K | -420K | -11.0K | -122K | - | - |
| EBITDA | -252K | -353K | -1.04M | -1.22M | -432K | -179K | 3.50M | 226K | 135K | - | - |
| Net Income | -248K | 406K | 406K | -1.14M | -622K | -369K | 3.29M | -11.0K | -93.2K | - | - |
| EPS | -0.01 | 0.01 | 0.01 | -0.02 | -0.01 | 0.00 | 0.02 | 0.00 | 0.00 | - | - |
| Balance Sheet | |||||||||||
| Total Assets | 1.03M | 1.29M | 1.29M | 1.31M | 1.40M | 1.49M | 1.08M | 1.08M | - | - | - |
| Total Liabilities | 373K | 867K | 867K | 1.59M | 5.66M | 6.12M | 2.12M | 2.00M | 122K | - | 122K |
| Shareholders' Equity | 660K | 419K | 419K | -289K | -4.26M | -4.63M | -1.04M | -914K | -122K | - | -747K |
| Cash & Short-term Investments | 698K | 754K | 754K | 75.0K | 190K | 285K | 86.4K | 86.4K | - | - | - |
| Total Debt | - | - | - | 611K | 4.20M | 4.42M | 775K | 651K | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -384K | -205K | - | -1.23M | -385K | -85.9K | 3.49M | -11.0K | -892K | -892K | - |
| Capital Expenditure | 631K | 631K | 0.00 | 631K | 1.96K | 2.03K | 2.11K | 0.00 | 3.00 | 0.00 | - |
| Free Cash Flow | -384K | -205K | - | -1.86M | -387K | -88.0K | 3.49M | -11.0K | -892K | -892K | - |
| Ratios | |||||||||||
| ROE | -37.6% | 96.9% | 96.9% | - | - | - | - | - | - | - | - |
| ROA | -24.1% | 31.6% | 31.6% | -87.3% | -44.4% | -24.8% | 304.5% | -1.0% | - | - | - |
| Net Profit Margin | -49.4% | 29.3% | 29.2% | -36.1% | -17.4% | -10.0% | 86.9% | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hypertension Diagnostics Inc dividends
Hypertension Diagnostics Inc has not paid dividends in the last 10 fiscal years.
Who owns Hypertension Diagnostics Inc
Ownership data of Hypertension Diagnostics Inc is not available yet.
Hypertension Diagnostics Inc company profile
- Company name
- Hypertension Diagnostics Inc
- Ticker
- HDII.US
- Exchange
- USA Stocks
- Listed since
- Aug 7, 1998
- Sector
- Financial Services
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- 550 Highway 7 East, Richmond Hill, ON, Canada, L4B 3Z4
- Phone
- 404-449-6151
- Website
- hypertensiondiagnostics.com
About Hypertension Diagnostics Inc
Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada.
Hypertension Diagnostics Inc management
1- Liangjian PengChief Executive Officer